Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
 
Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525 
  
 
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530 
     free
  
Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531 
     free
      free 
   English Wikipedia
  Nephropedia Template TP (
  Twit Text
 
  DeepDyve Pubget Overpricing |    
 
  lüll Methylene blue in the treatment and prevention of ifosfamide-induced  encephalopathy: report of 12 cases and a review of the literature Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prove A; Vermorken JBBr J Cancer  2000[Jan]; 82 (2): 291-4Ifosfamide is an alkylating agent used in the treatment of a variety of solid  tumours. Ten to 15% of patients treated with ifosfamide develop an  encephalopathy. Methylene blue (MB) may be used in the treatment of this  encephalopathy. The purpose of this study was to evaluate the neuroprotective  effect of MB in these patients and to review the literature. Between 1993 and  1997, 52 patients (age 16-77 years) with solid tumours were treated with  ifosfamide in dosages ranging from 3 to 5 g m(-2) q3w when given in combination  schedules and up to 12 g m(-2) q4w when given as a single agent. Twelve patients  developed central nervous system (CNS) depression, defined as National Cancer  Institute Common Toxicity Criteria (NCI-CTC) neurocortical toxicity grade 2 or  higher. Eight were treated with MB at a dose of 6 x 50 mg day(-1) intravenously  (i.v.). Four recovered fully within 24 h, two recovered partially after 24 h and  completely after 48 h while two recovered only after 72 h. Four patients did not  receive MB and all recovered only after 48 h. Three patients received prophylaxis  with MB at a dose of 4 x 50 mg day(-1) i.v. for the subsequent chemotherapy  cycles. Two developed milder encephalopathy; one had no CNS depression at all. We  conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.  Our findings suggest that it may also be used as a prophylactic agent.|Adolescent[MESH]|Adult[MESH]|Aged[MESH]|Antineoplastic Agents, Alkylating/*adverse effects/therapeutic use[MESH]|Brain Diseases/*chemically induced/*drug therapy[MESH]|Dose-Response Relationship, Drug[MESH]|Enzyme Inhibitors/pharmacology/*therapeutic use[MESH]|Female[MESH]|Humans[MESH]|Ifosfamide/*adverse effects/therapeutic use[MESH]|Infusions, Intravenous[MESH]|Male[MESH]|Methylene Blue/pharmacology/*therapeutic use[MESH]|Middle Aged[MESH]|Neoplasms/drug therapy[MESH]|Treatment Outcome[MESH] |